Stock analysts expect Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN – Get a rating) to report sales of $191.72 million for the current quarter, Zacks Investment Research reports. Six analysts have made earnings estimates for Biohaven Pharmaceutical, with the lowest sales estimate at $171.03 million and the highest estimate at $225.00 million. Biohaven Pharmaceutical recorded sales of $43.82 million in the same quarter last year, which would indicate a positive growth rate of 337.5% year over year. The company is expected to announce its next quarterly results on Monday, January 1.
On average, analysts expect Biohaven Pharmaceutical to post annual revenue of $943.75 million for the current fiscal year, with estimates ranging from $884.00 million to $1.04 billion. of dollars. For next year, analysts expect the company to post sales of $1.38 billion, with estimates ranging from $1.22 billion to $1.48 billion. Zacks sales calculations are an average average based on a survey of research analysts who cover Biohaven Pharmaceutical.
Biohaven Pharmaceutical (NYSE: BHVN – Get a rating) last released its quarterly results on Thursday, February 24. The company reported ($3.01) EPS for the quarter, missing analyst consensus estimates of ($2.04) by ($0.97). The company posted revenue of $190.01 million in the quarter, versus analyst estimates of $175.54 million. The company’s quarterly revenue increased 441.1% year over year. During the same period last year, the company posted ($3.62) EPS.
A number of research companies have weighed in on BHVN recently. Mizuho raised its price target on Biohaven Pharmaceutical from $144.00 to $154.00 and gave the stock a “buy” rating in a Thursday, March 3 research note. UBS Group raised its price target on Biohaven Pharmaceutical from $150.00 to $160.00 in a Tuesday, January 4 research note. Morgan Stanley raised its price target on Biohaven Pharmaceutical from $145.00 to $148.00 and gave the stock an “equal weight” rating in a Friday, Jan. 7 research note. Finally, HC Wainwright reaffirmed a “buy” rating and posted a $160.00 price target on Biohaven Pharmaceutical shares in a research note on Friday, January 7. Three investment analysts gave the stock a hold rating and eight gave the stock a buy rating. According to MarketBeat.com, the stock currently has a consensus buy quote and a consensus price target of $148.45.
BHVN shares opened at $117.48 on Tuesday. The stock has a market capitalization of $8.29 billion, a price-earnings ratio of -8.98 and a beta of 1.08. The company has a 50-day simple moving average of $124.78 and a two-hundred-day simple moving average of $126.98. Biohaven Pharmaceutical has a 52 week low of $62.57 and a 52 week high of $151.51.
In other news, CAD George C. Clark sold 9,375 shares of the company in a transaction that took place on Wednesday, January 19. The stock was sold at an average price of $117.01, for a total value of $1,096,968.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, accessible via this hyperlink. 12.40% of the shares are held by insiders of the company.
Hedge funds and other institutional investors have recently changed their holdings in the company. Russell Investments Group Ltd. increased its holdings of Biohaven Pharmaceutical shares by 14.5% in the third quarter. Russell Investments Group Ltd. now owns 61,683 shares of the company worth $8,567,000 after purchasing an additional 7,791 shares during the period. Two Sigma Advisers LP purchased a new equity stake in Biohaven Pharmaceutical in the third quarter worth approximately $5,404,000. Montag A & Associates Inc. bought a new position in Biohaven Pharmaceutical during Q3 at a value of $96,000. Balyasny Asset Management LLC acquired a new position in Biohaven Pharmaceutical during Q3 for a value of $4,785,000. Finally, Teacher Retirement System of Texas increased its stake in Biohaven Pharmaceutical by 40.3% during the 3rd quarter. Teacher Retirement System of Texas now owns 9,254 shares of the company worth $1,285,000 after purchasing 2,660 additional shares during the period. Hedge funds and other institutional investors hold 91.73% of the company’s shares.
Biohaven Pharmaceutical Company Profile (Get a rating)
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, is developing product candidates targeting neurological and neuropsychiatric diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as the development of Rimegepant for the preventive treatment of migraine; Zavegepant which is in Phase III clinical trials for the acute and preventive treatment of migraine, as well as for respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Biohaven Pharmaceutical right now?
Before you consider Biohaven Pharmaceutical, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Biohaven Pharmaceutical didn’t make the list.
Although Biohaven Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here